VRAX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 30, 2026
Report Source: 2026 2nd Quarter Report
Virax Biolabs Group Ltd. Stock Analysis VRAX
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Read More Virax Biolabs Group Ltd (VRAX) Chart
Key Statistics of Virax Biolabs Group Ltd (VRAX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.14Volume
1.74MP/E Ratio (TTM)
-52 Week Range
Market Cap
2.42MAvg. Volume
17.84MDividend Yield
-Financial Metrics & Statements of Virax Biolabs Group Ltd (VRAX)
FAQ's for Virax Biolabs Group Ltd (VRAX)
- According to Musaffa’s Shariah screening methodology, Virax Biolabs Group Ltd (VRAX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.